

PACIFIC INDUSTRIES LIMITED

Regd. Office : Village Bedla, Udaipur 313011, Rajasthan
 Phone No. 91-294-2440196/2440388, Fax: +91-294-2440780
 Website: www.pacificindustriesltd.com, E-mail: pilnorth@pacificgranites.com,
 CIN-L14101RJ1989PLC099253

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March, 2025

(Rs. In Lakhs)

PARTICULARS	Standalone					Consolidated				
	Quarter ended 31st March 2025 (Audited)	Quarter ended 31st March 2024 (Audited)	Quarter ended 31st December 2024 (Un-audited)	Year ended 31st March 2025 (Audited)	Year ended 31st March 2024 (Audited)	Quarter ended 31st March 2025 (Audited)	Quarter ended 31st March 2024 (Audited)	Quarter ended 31st December 2024 (Un-audited)	Year ended 31st March 2025 (Audited)	Year ended 31st March 2024 (Audited)
Total income from operations (Net)	6,134.16	6,029.29	6,505.84	25,099.70	19,522.49	6,233.25	6,278.34	6,555.14	25,711.64	20,673.50
Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	194.18	317.98	170.67	637.96	1,021.39	227.47	533.97	190.02	962.56	1,331.81
Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	194.18	317.98	170.67	637.96	1,021.39	227.47	533.97	190.02	962.56	1,331.81
Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	206.88	297.97	116.84	525.46	946.18	231.24	471.95	131.56	764.76	1,187.79
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax))	230.82	290.11	112.68	557.43	977.61	255.73	534.11	127.39	797.04	1,289.23
Equity share Capital	689.27	689.27	689.27	689.27	689.27	689.27	689.27	689.27	689.27	689.27
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	16496.92	15939.48	-	-	-	43474.04	42677.00
Earning Per Share (for Rs. 10/- each) (for continuing and discontinuing operations)										
1. Basic:	3.00	3.00	4.32	13.73	13.73	3.35	6.85	1.91	11.10	17.23
2. Diluted:	3.00	3.00	4.32	13.73	13.73	3.35	6.85	1.91	11.10	17.23

(A) The above Audited Financial Results for the quarter and year ended March, 31 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 27th May 2025.
 (b) Note:- The above is an extract of the quarterly and yearly results filed with the stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirement) Regulation 2015. The full format of the audited results for the quarter and year ended 31.03.2025 are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.pacificindustriesltd.com)

On behalf of the Board
 For PACIFIC INDUSTRIES LIMITED
 Sd/-
 Sachin Shah
 (Company Secretary)

Place : Udaipur
 Date : 27.05.2025

AnZen

INDIA ENERGY TRUST

Anzen India Energy Yield Plus Trust

Registered Office: Plot No.294/3, Edelweiss House, Off CST Road, Kalina, Santacruz East, MUMBAI, MAHARASHTRA, 400098
 SEBI Registration Number: IN/InvIT/21-22/0020, Email-ID: InvITinvestorgrievances@eaaai.in; Website: www.anzenenergy.in

EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(All amounts in INR million, except as stated)

Particulars	Quarter Ended		Year Ended	
	March 31, 2025 (Audited)	December 31, 2024 (Unaudited)	March 31, 2025 (Audited)	March 31, 2024 (Audited)
1 Total Income from Operations	768.05	632.40	623.03	2,677.17
2 Net Profit / (Loss) for the period/year (before Tax, Exceptional and/or Extraordinary item)	(78.01)	(29.72)	(85.73)	(155.47)
3 Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(78.01)	(29.72)	(85.73)	(155.47)
4 Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	(75.87)	(31.90)	(88.87)	(162.34)
5 Total Comprehensive income [(Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive income (after tax)]	(75.96)	(31.91)	(88.99)	(162.49)
6 Paid up Unit Capital (net of issue expenses) (face value of INR 100/- each)	19,571.64	15,624.79	15,624.79	19,571.64
7 Reserves (excluding Revaluation Reserve)	(4,067.09)	(3,604.03)	(2,356.20)	(4,067.09)
8 Net worth	15,504.55	12,020.76	13,268.59	15,504.55
9 Earnings per unit (INR per unit) - Basic & Diluted	(0.47)	(0.20)	(0.56)	(1.01)
10 Asset Cover (in times)	1.87	2.64	2.81	1.87
11 Debt Equity Ratio (in times)	1.22	0.62	0.56	1.22
12 Debt Service Coverage Ratio (in times)	2.13	3.49	3.39	2.98
13 Interest Service Coverage Ratio (in times)	2.41	3.49	3.39	3.11

EXTRACT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

(All amounts in INR million, except as stated)

Particulars	Quarter Ended		Year Ended	
	March 31, 2025 (Audited)	December 31, 2024 (Unaudited)	March 31, 2024 (Audited)	March 31, 2024 (Audited)
1 Total Income from Operations	601.95	542.45	537.77	2,228.45
2 Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Item)	378.31	375.50	370.62	1,495.12
3 Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	378.31	375.50	370.62	1,495.12
4 Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	371.66	373.32	367.48	1,479.46
5 Total Comprehensive income [(Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive income (after tax)]	371.66	373.32	367.48	1,479.46
6 Unit Capital (net of issue expenses) (Face value of INR 100 per unit)	19,571.64	15,624.79	15,624.79	19,571.64
7 Reserves (excluding Revaluation Reserve)	156.32	171.76	225.26	156.32
8 Net worth	19,727.96	15,796.55	15,850.05	19,727.96
9 Earnings per unit (INR per unit) - Basic & Diluted	2.31	2.36	2.33	9.19
10 Asset Cover (in times)	2.03	3.10	3.11	2.03
11 Debt Equity Ratio (in times)	0.96	0.47	0.47	0.96
12 Debt Service Coverage Ratio (in times)	2.39	3.33	3.34	3.01
13 Interest Service Coverage Ratio (in times)	2.78	3.33	3.34	3.16

- Notes:**
- The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 27, 2025.
 - On 8 March 2025, the Trust acquired 100% of paid up equity capital of Solzen Urja Private Limited (formerly known as Renew Sun Waves Private Limited) from ReNew Private Limited pursuant to Share Purchase Agreement dated 19 December 2024 ("SPA").
 - In the current quarter, the Trust has issued 38,193,900 units at a price of INR 105.06 per unit to institutional investors and has raised funds of INR 4,012.65 million.
 - The Trust has allotted 70,000 Secured, Rated, Listed, Redeemable, Non-Convertible Debentures of face value of INR 0.10 million each for an aggregate amount of INR 7,000 million on 6 March 2025 on private placement basis.
 - The Trust retained its credit ratings of "CRISIL AAA/Stable" from CRISIL as on 07 April 2025 and "IND AAA/Stable" from India Ratings as on 22 April 2025.
 - The Board of Directors of the Investment Manager approved a distribution of INR 2.45 per unit for the quarter ended 31 March 2025 to be paid within five working days from the record date.
 - The above is an extract of the detailed format of financial results filed with the stock exchange(s). The full format of financial results is available on the website of the stock exchanges i.e. www.bseindia.com, www.nseindia.com and on the website of Anzen - www.anzenenergy.in

For Anzen India Energy Yield Plus Trust
 Sd/-
 Ranjita Deo
 Whole Time Director & Chief Investment Officer
 DIN No.: 09609160

May 27, 2025, Mumbai

NATCO Pharma Limited

Regd. Office: Natco House, Road No.2, Banjara Hills, Hyderabad-500 034, Phone: 040-23547532,
 Email: investors@natcopharma.co.in CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Extract of Consolidated Audited Financial Results for the Quarter and Year Ended March 31, 2025

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated				
		Quarter ended 3/31/2025 (Refer Note-4)	Quarter ended 12/31/2024 (Unaudited)	Quarter ended 3/31/2024 (Refer Note-4)	Year ended 3/31/2025 (Audited)	Year ended 3/31/2024 (Audited)
1	Revenue from operations	12,210	4,748	10,683	44,295	39,988
2	Profit for the period (before Tax, Exceptional and/or Extraordinary items)	5,059	1,637	4,776	22,914	16,735
3	Profit for the period before tax (after Exceptional and/or Extraordinary items)	5,059	1,637	4,776	22,914	16,735
4	Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	4,066	1,330	3,863	18,854	13,883
5	Total Comprehensive Income for the period attributable to owners of the parent	3,884	1,224	3,738	18,614	14,032
6	Paid-up equity share capital of Rs.2 each	358	358	358	358	358
7	Other equity (Revaluation reserve Rs.II)				75,712	58,173
8	Earnings Per Share (in Rupees) per Rs.2/-share (non-annualised)					
	Basic	22.70	7.43	21.56	105.26	77.34
	Diluted	22.70	7.43	21.56	105.26	77.34

Notes:
 1 Summarized Audited Standalone Financial Results of the Company is as under

All amounts in Indian Rupees millions

Sl. No.	Particulars	Standalone				
		Quarter ended 3/31/2025 (Refer Note-4)	Quarter ended 12/31/2024 (Unaudited)	Quarter ended 3/31/2024 (Refer Note-4)	Year ended 3/31/2025 (Audited)	Year ended 3/31/2024 (Audited)
1	Revenue from operations	11,574	4,076	9,648	40,945	35,689
2	Profit before tax	5,208	1,503	4,325	22,260	15,553
3	Net profit for the period/ year	4,281	1,249	3,491	18,504	13,066
4	Total comprehensive income	4,049	1,403	3,473	18,491	13,142

- The above is an extract of the detailed format of Financial Results for the quarter and year ended 31 March, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Annual Financial Results is available on the Stock Exchange website: www.nseindia.com and www.bseindia.com and also on the Company's website www.natcopharma.co.in.
- The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meetings held on 28 May, 2025.
- The results for the quarters ended 31 March 2025 and 31 March 2024 are the balancing figures between audited consolidated figures and audited standalone figures in respect of the full financial years and the published unaudited year to date consolidated figures and standalone figures upto third quarter of the respective financial years.

Place: Hyderabad
 Date: 28 May 2025

for NATCO PHARMA LIMITED
 Sd/- V.C. Nannapaneni
 Chairman & Managing Director



This is only an advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States or otherwise outside India. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated April 24, 2025 the "Letter of Offer" or "LOF" filed with the stock exchange, namely BSE Limited ("BSE") and the Securities and the Exchange Board of India ("SEBI") for information and dissemination on the SEBI's website pursuant to proviso to Regulation 3 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations").



REMEDIUM LIFECARE LIMITED

Corporate Identification Number: L24100MH1988PLC343805
 Registered Office: Office No. 9, K Raheja Prime, Marol Industrial Estate, Behind Ravi Vihar Hotel, Sagbaug Road, Marol, Andheri East, Marol Naka, Mumbai - 400059, Maharashtra
 Contact Person: Neeraj Ramashankar Yadav, Company Secretary and Compliance Officer;
 Contact No: +91 8424892518 | Email-ID : csremilife@gmail.com | Website: www.remilife.com

Our Company, was incorporated as 'Roxxy Engineers Private Limited' under the Companies Act, 1956, received its Certificate of Incorporation from the Registrar of Companies, Jalandhar, on February 19, 1988. Subsequently our Company was converted into public limited company with effect from May 1, 1995, and name of our Company was changed to 'Roxxy Exports Limited'. Following a special resolution approved by shareholders at the Annual General Meeting held on September 30, 2019, our registered office was shifted to 416 D, 4th floor, Dattani Plaza, Safed Pool, Sakinaka, Andheri East, Mumbai, India. Further, on November 16, 2020, the name of our Company was changed from 'Roxxy Exports Limited' to 'Remedium Lifecare Limited' as per the provision of the Companies Act 2013 as on November 16, 2020 upon Fresh Certificate of Incorporation issued pursuant to change of name by the Registrar of Companies, Mumbai. Additionally, on May 11, 2021, pursuant to resolution dated May 11, 2021 passed by the Board of Directors, our registered office was changed at 6th/01, Hyde Park, CTS No. 680, Saki Vihar Rd, Saki Naka, Mumbai, India. Most recently, on May 30, 2023, the Board of Directors passed a resolution to change our registered office to 9, K Raheja Prime, Marol Industrial Estate, Behind Ravi Vihar Hotel, Sagbaug Road, Marol, Andheri East, Marol Naka, Mumbai - 400059, Maharashtra. Our Company through Initial Public Offer (IPO) listed on BSE Exchange vide their listing approval dated January 12, 2016, see 'General Information' on page 45 of this Letter of Offer.

PROMOTER OF OUR COMPANY: SIDDHARTH CHIMANLAL SHAH NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF REMEDIUM LIFECARE LIMITED ("OUR COMPANY OR COMPANY") ONLY
RIGHTS ISSUE OF 49,19,04,000* FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 1/- EACH ("RIGHTS EQUITY SHARES") AT A PRICE OF ₹ 1.00/- PER EQUITY SHARE ("ISSUE PRICE") FOR AN AMOUNT NOT EXCEEDING ₹ 4919.04 LAKHS ON A RIGHTS ISSUE BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF REMEDIUM LIFECARE LIMITED IN THE RATIO OF 61 RIGHTS EQUITY SHARES FOR EVERY 50 EQUITY SHARES HELD BY SUCH ELIGIBLE EQUITY SHAREHOLDERS AS ON THE RECORD DATE, APRIL 15, 2025, ("ISSUE"). THE ISSUE PRICE IS 1.00 TIMES THE FACE VALUE OF THE EQUITY SHARE. FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED 'TERMS OF THE ISSUE' BEGINNING ON PAGE 202 OF THIS LETTER OF OFFER.

BASIS OF ALLOTMENT

NOTICE TO ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY

The Board of Directors of Remedium Lifecare Limited wishes to thank all its shareholders and investors for their response to the issue which opened for subscription on April 30, 2025 and closed on May 14, 2025 and the last date for market renunciation of Rights Entitlements was May 9, 2025. Out of the total 8258 Applications for 51,85,63,855 Equity Shares, 295 Applications for 3,96,90,526 Equity Shares were rejected on the basis of Ground for technical rejections as disclosed in the Letter of Offer.

The total number of fully valid applications received were 7963 Applications for 47,87,90,132 Equity Shares. In accordance with the Letter of Offer and on the basis of allotment finalized on May 22, 2025 in consultation with the Registrar to the Issue and BSE Limited, the Designated Stock Exchange for the Issue, the Company has on May 22, 2025 allotted 47,87,90,132 Equity Shares to the successful Applicants. All valid applications have been considered for Allotment.

1. The break-up of valid Applications (including ASBA applications) is given below:

Category	Number of Valid Applications (including ASBA applications) Received	No. of Rights Equity Shares accepted and allotted against Right Entitlements (A)	No. of Rights Equity Shares accepted and allotted against additional equity shares applied (B)	Total Rights Equity Shares Accepted and Allotted (A+B)
Shareholders	7805	8,08,50,204	11,99,19,113	20,07,69,317
Renounees	158	58,21,638	27,21,99,177	27,80,20,815
Total	7963	8,66,71,842	39,21,18,290	47,87,90,132

2. Information regarding total Applications received (including ASBA applications received):

Category	Applications received		Rights Equity Shares Applied for			Rights Equity Shares Allotted		
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Shareholders	8,100	98.09	24,05,43,040	24,05,43,040	46.39	20,07,69,317	20,07,69,317	41.93
Renounees	158	1.91	27,80,20,815	27,80,20,815	53.61	27,80,20,815	27,80,20,815	58.07
Total	8258	100	51,85,63,855	51,85,63,855	100	47,87,90,132	47,87,90,132	100

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation and reason for rejection, as applicable, to the investors has been completed on May 22, 2025. The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on May 22, 2025. The Listing application was executed with BSE on May 23, 2025 and subsequently, the listing approval was received on May 27, 2025. The credit of Equity Shares in dematerialized form to respective demat accounts of allottees has been completed on May 27, 2025. For further details please see "Terms of the Issue- Allotment Advices/Refund Orders on page number 234 of the LOF Pursuant to the listing and trading approvals granted to be granted by BSE and NSE, the Rights Equity Shares Allotted in the issue is expected to commence trading on BSE on or before June, 2025. In accordance with the SEBI circular, the request for extinguishment of rights entitlement with NSDL and CDSL has been completed on May 26, 2025.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.
DISCLAIMER CLAUSE OF SEBI: The Letter of Offer has not been filed with in terms of SEBI ICDR Regulations as the size of the issue is up to ₹ 4919.04 Lakhs which is less than Rs. 5000.00 Lakhs. Only the Letter of Offer will be filed with the SEBI for information and dissemination on the SEBI's website. The Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" on page 196 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The Investors are advised to refer to the full text of the Disclaimer provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE Limited" on page 196 of the Letter of Offer.

REGISTRAR TO THE ISSUE	COMPANY SECRETARY & COMPLIANCE OFFICER
 BIGSHARE SERVICES PRIVATE LIMITED Office No S6-2, 6th floor Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093 Tel No.: 022-62638200/122-62638280 Email: rightsissue@bigshareonline.com Investor grievance e-mail: investor@bigshareonline.com Contact Person: Mr. Jibu Jhon Website: www.bigshareonline.com SEBI Registration No: INR000001385	 REMEDIUM LIFECARE LIMITED Corporate Identification Number: L24100MH1988PLC343805 Registered Office: Office No. 9, K Raheja Prime, Marol Industrial Estate, Behind Ravi Vihar Hotel, Sagbaug Road, Marol, Andheri East, Marol Naka, Mumbai - 400059, Maharashtra Contact No: +91 8424892518 Contact Person: Neeraj Ramashankar Yadav, Company Secretary and Compliance Officer; Email-ID: csremilife@gmail.com Website: www.remilife.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs in case of ASBA process, giving full details such as name, address of the Applicant contact number(s), e-mail address of the sole first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the case may be, was submitted by the investors along with a photocopy of the acknowledgement slip (in case of ASBA process).